ClinicalTrials.gg
Not yet recruitingNCT07550231Updated Apr 24, 2026

Determining the Optimal Dose of AD-211 in Patients With Osteoarthritis of the Knee

A Phase 2 interventional study of AD-211-L and AD-211-M in Osteoarthritis of the Knees, sponsored by Addpharma Inc.. Not yet recruiting. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Addpharma Inc. (part of Yuhan Corporation) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to determine the optimal dose of AD-211 in patients with osteoarthritis of the knee.

Read the detailed description

Osteoarthritis of the knee

02

Conditions studied

  • Osteoarthritis of the Knees
03

In context

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

This study's planned enrollment of 200 is above the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.

Browse Osteoarthritis, Knee studies →

Lead sponsor

Addpharma Inc. is the lead sponsor of 58 studies on the registry; 25 are open to participants now.

First submitted after Addpharma Inc. became part of Yuhan Corporation.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Patients with osteoarthritis of the Knee
  • Other inclusions applied

Exclusion criteria

Exclusion Criteria:

  • Patients with secondary osteoarthritis of the knee
  • Other exclusions applied
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    AD-211-L Group

    1 Week: twice daily; 2 tablets per dose (AD-211-L + placebo to AD-2113). 12 Weeks: twice daily; 3 tablets per dose (AD-211-L + placebo to AD-211-H + placebo to AD-2113).

    Drug: AD-211-L · Drug: Placebo to AD-211-H · Drug: Placebo to AD-2113

  • Experimental
    AD-211-M Group

    1 Week: twice daily; 2 tablets per dose AD-211-M + placebo to AD-2113). 12 Weeks: twice daily; 3 tablets per dose (AD-211-M + placebo to AD-211-H + placebo to AD-2113).

    Drug: AD-211-M · Drug: Placebo to AD-211-H · Drug: Placebo to AD-2113

  • Experimental
    AD-211-H Group

    1 Week: twice daily; 2 tablets per dose (AD-211-M + placebo to AD-2113). 12 Weeks: twice daily; 3 tablets per dose (AD-211-H + placebo to AD-211-L/M + placebo to AD-2113).

    Drug: AD-211-M · Drug: AD-211-H · Drug: Placebo to AD-211-L/M · Drug: Placebo to AD-2113

  • Active comparator
    AD-2113 Group

    1 Week: twice daily; 2 tablets per dose (AD-2113 + placebo to AD-211-L/M). 12 Weeks: twice daily; 3 tablets per dose (AD-2113 + placebo to AD-211-L/M + placebo to AD-211-H).

    Drug: AD-2113 · Drug: Placebo to AD-211-L/M · Drug: Placebo to AD-211-H

Interventions

  • DrugAD-211-L

    Per oral, 1 tablet twice daily during the treatment period.

  • DrugAD-211-M

    Per oral, 1 tablet twice daily during the treatment period.

  • DrugAD-211-H

    Per oral, 1 tablet twice daily during the treatment period.

  • DrugAD-2113

    Per oral, 1 tablet twice daily during the treatment period.

  • DrugPlacebo to AD-211-L/M

    Per oral, 1 tablet twice daily during the treatment period.

  • DrugPlacebo to AD-211-H

    Per oral, 1 tablet twice daily during the treatment period.

  • DrugPlacebo to AD-2113

    Per oral, 1 tablet twice daily during the treatment period.

06

What researchers measure

Primary outcomes

  1. Change from baseline in 100 mm Pain VAS score during activity over the past 24 hours in the target knee

    Time frame: Baseline to Week13

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Mar 2027, 9 months later.

Of 58 industry-sponsored phase 2 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 25. This study's planned 9 months is below that.

Counting every sponsor, half of 101 studies reached it within 20 months; a quarter within 12 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2026
First posted
Apr 24, 2026
StartEst.
Jun 2026
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07550231
Lead sponsor
Addpharma Inc.
Responsible party
Sponsor
First posted
Apr 24, 2026
Start date
Jun 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Apr 24, 2026

Study contacts

Hyeji Lee
Contact
hjlee@addpharma.co.kr
+82318915604
Jung Yoon Choi
principal investigator · Daegu Catholic University Medical Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion